Dova Pharmaceuticals Inc.
Dova Pharmaceuticals Inc. (DOVA): 1 pipeline candidate · ~11 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
11.0 months
D/E 1.38 · 0% dilution
Lead: Phase 3
1 candidate
N/A
N/A
A transparent, data-derived signal for Dova Pharmaceuticals Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$68.4M
Quarterly Burn
$19.4M
Runway
11.0 mo
Revenue
$3.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| doptelet | Phase 3 |
Frequently asked questions
How many drug candidates are in Dova Pharmaceuticals Inc.'s pipeline?
Dova Pharmaceuticals Inc. (DOVA) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Dova Pharmaceuticals Inc.'s lead drug candidate?
Dova Pharmaceuticals Inc.'s most advanced tracked candidate is doptelet (Phase 3) for Chemotherapy-induced thrombocytopenia (CIT).
What is Dova Pharmaceuticals Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Dova Pharmaceuticals Inc. has approximately 11.0 months of cash runway.
Who is the CEO of Dova Pharmaceuticals Inc.?
United Therapeutics Corporation is the chief executive officer of Dova Pharmaceuticals Inc. (DOVA).
Get the full picture on Dova Pharmaceuticals Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.